Tacrolimus

Tacrolimus (FK506), a macrocyclic lactone, binds to FK506 binding protein (FKBP) to form a complex. Tacrolimus inhibits calcineurin phosphatase, which inhibits T-lymphocyte signal transduction and IL-2 transcription. Immunosuppressive properties.

Product information

CAS Number: 104987-11-3

Molecular Weight: 804.02

Formula: C44H69NO12

Synonym:

FK 506

FK-506

FK506

fujimycin

Prograf

Protopic

Advagraf

Astagraf XL

Related CAS Number:

109581-93-3 (Tacrolimus hydrate)

Chemical Name: (1R, 9S, 12S, 13R, 14S, 17R, 21S, 23S, 24R, 25S, 27R)-1, 14-dihydroxy-12-[(1E)-1-[(1R, 3R, 4R)-4-hydroxy-3-methoxycyclohexyl]prop-1-en-2-yl]-23, 25-dimethoxy-13, 19, 21, 27-tetramethyl-17-(prop-2-en-1-yl)-11, 28-dioxa-4-azatricyclo[22.3.1.0, ]octacos-18-ene-2, 3, 10, 16-tetrone

Smiles: CC1C[C@H](C)C[C@H](OC)[C@H]2O[C@](O)([C@H](C)C[C@@H]2OC)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@@H]([C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)C=1)/C(/C)=C/[C@H]1C[C@@H](OC)[C@H](O)CC1 |c:46|

InChiKey: QJJXYPPXXYFBGM-LJIGMGMYSA-N

InChi: InChI=1S/C44H69NO12/c1-10-13-31-19-25(2)18-26(3)20-37(54-8)40-38(55-9)22-28(5)44(52,57-40)41(49)42(50)45-17-12-11-14-32(45)43(51)56-39(29(6)34(47)24-35(31)48)27(4)21-30-15-16-33(46)36(23-30)53-7/h10,19,21,26,28-34,36-40,46-47,52H,1,11-18,20,22-24H2,2-9H3/b25-19-,27-21+/t26-,28+,29+,30-,31+,32-,33+,34-,36+,37-,38-,39+,40+,44+/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO: 94 mg/mL(116.91 mM). Water: Insoluble.

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

FK-506 and cyclosporin A block translocation of the cytoplasmic component without affecting synthesis of the nuclear subunit in T lymphocytes. FK-506 prevents T-cell proliferation by inhibiting a Ca(2+)-dependent event required for induction of interleukin-2 transcription. FK 506 binds to distinct families of intracellular proteins (immunophilins) termed cyclophilins and FK 506-binding proteins (FKBPs). FK-506 specifically inhibits cellular calcineurin at drug concentrations that inhibit interleukin 2 production in activated T cells. FK-506 and CsA exert nearly identical biological effects in cells by inhibiting the same subset of early calcium-associated events involved in lymphokine expression, apoptosis, and degranulation. FK-506 binds to a family of intracellular receptors termed the FK-506 binding proteins (FKBPs).

In Vivo:

FK-506 results in increase in the paw and tail withdrawal threshold as revealed by behavioral pain assessment in rats against hyperalgesic and allodynic stimuli. FK-506 also leads to a decrease in the serum nitrate and thiobarbituric acid reactive substance (TBARS) levels along with reduction in tissue myeloperoxidase (MPO) and total calcium levels, whereas, rise in tissue reduced glutathione levels in rats. FK-506 ameliorates the increase in the neuronal edema and axonal degeneration in rats with ischemia reperfusion (I/R).

References:

1. Fruman DA, et al. Proc Natl Acad Sci U S A, 1992, 89(9), 3686-3690.
2. S J O Keefe, et al. Nature . 1992 Jun 25;357(6380):692-4.
3. Flanagan WM, et al. Nature, 1991, 352(6338), 803-807.

Products are for research use only. Not for human use.